Effect of combination therapy of Hetrombopag and rhTPO on platelet parameters and bleeding in patients with immune thrombocytopenia
Objective:To investigate the effects of combination therapy with recombinant human thrombopoietin(rhTPO)and Hetrombopag on platelet parameters and bleeding in patients with immune thrombocytopenia(ITP).Methods:Select 62 cases of ITP patients treated in our hospital from January 2022 to December 2023 as research subjects,and randomly divide them into the observation group and the control group,each with 31 cases,using the method of drawing black and white lots.The control group received rhTPO treatment(300 U·kg-1,once daily),while the observation group received additional Hetrombopag treatment(initial dose of 2.5 mg·d-1)on this basis.After 21 days of treatment,the therapeutic effects of the two groups were compared.An automatic blood analyzer was used to detect the following platelet parameters:Mean platelet volume(MPV);the ratio of large(mature)platelets to total platelet count:Platelet large cell ratio(P-LCR);the ratio of platelet volume to total blood volume:Plateletcrit(PCT);and Platelet count(PLT).During the treatment period,the bleeding rate was evaluated using the WHO bleeding grading criteria,and the difference in the rate of platelet transfusion was also compared between the two groups.Results:The overall effective rate in the observation group was significantly higher than that in the control group(P<0.05);after treatment,the platelet parameters P-LCR levels in both groups were significantly reduced compared to before treatment,and the observation group was significantly lower than the control group(P<0.05);the levels of MPV,PCT,and PLT were significantly increased compared to before treatment,and the observation group was significantly higher than the control group(P<0.05);the grade 1 bleeding rate and the rate of platelet transfusion required in the observation group were significantly lower than those in the control group(P<0.05),and there was no significant difference in the grade 2 bleeding rate between the two groups(P>0.05).Conclusion:The Hetrombopag and rhTPO treatment for ITP is effective,can improve platelet parameters,and reduce the need for bleeding and transfusion.
HetrombopagRecombinant human thrombopoietinImmune thrombocytopeniaPlatelet parameters
NETL
NSTL
万方数据
